BGLC

BioNexus Gene Lab Corp.

NasdaqCMUSDEQUITY DELAYED

1.55

▼ 0.04 (2.30%)

MARKET · —

Price

Open

1.58

Prev close

1.59

Day high

1.70

Day low

1.59

Volume

985

Market cap

—

P/E (TTM)

—

52W range

1.07 – 6.10

Trailing performance

Price return · vs SPY

Returnvs SPY

+1.27% +2.6%

+3.25% -0.5%

-21.29% -24.4%

-34.57% -45.6%

YTD

-59.75% -72.0%

-70.17% -90.2%

-77.92% -152.1%

— —

Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.

Fundamentals

TTM · reported

Market cap—

Enterprise value—

Revenue (TTM)—

Gross profit—

EBITDA—

Net income—

EPS (TTM)—

Free cash flow—

Total cash—

Total debt—

Book value / share—

Shares outstanding—

Float—

Short % of float—

Dividend yield—

Beta (5Y)—

Valuation & profitability ratios

Account required

Trailing P/E—

Forward P/E—

PEG ratio—

Price / sales—

Price / book—

EV / revenue—

EV / EBITDA—

Gross margin—

Operating margin—

Profit margin—

Return on equity—

Return on assets—

Debt / equity—

Current ratio—

Free account required

Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.

Create free account Sign in

Analyst targets & ownership

Account required

Mean target—

High target—

Low target—

Implied upside—

Analyst count—

Consensus—

Strong buy / Buy— / —

Hold—

Sell / Strong sell— / —

Held by insiders—

Held by institutions—

Institutions holding—

Free account required

Price targets, consensus spread, insider and institutional ownership.

Create free account Sign in

Moving averages & technicals

Computed from 2Y daily closes

SMA 10

1.57

-1.39% from price

SMA 20

1.51

+5.41% from price

SMA 50

1.79

-11.12% from price

SMA 100

1.97

-21.45% from price

SMA 200

2.70

-41.07% from price

EMA 12

1.57

-1.07% from price

EMA 26

1.60

-3.28% from price

EMA 50

1.73

-10.44% from price

RSI (14)

48.6

Neutral

MACD (12,26,9)

-0.04

Hist 0.03

ATR (14)

0.10

6.47% of price

Realised vol 30D

61.2%

Annualised

Bollinger upper

1.72

20, 2σ

Bollinger lower

1.30

20, 2σ

50 / 200 cross

Death

1.79 vs 2.70

Trend bias

Below 200

-41.07%

Risk profile

Daily returns · 1Y window

Beta vs SPY

1.24

More volatile than market

Correlation to SPY

0.22

Largely independent

Realised vol 30D

61.2%

Annualised

Market vol 1Y

12.9%

SPY, annualised

Max drawdown 1Y

-78.0%

Peak to trough

Max drawdown 5Y

-99.5%

Peak to trough

ATR 14

0.10

6.47% of price

Beta (reported)

—

5Y monthly, from filing

Options chain

Account required

ExpirySpot 1.55

Calls

Strike	Last	Bid	Ask	Vol	OI	IV
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%

Puts

Strike	Last	Bid	Ask	Vol	OI	IV
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%

Free account required

Every listed expiry, both sides of the book, with volume, open interest and implied volatility.

Create free account Sign in

Headlines

BGLC · links out to the publisher

BioNexus Advances VitaGuard™ Southeast Asia Rollout Following China Working Visit GlobeNewswire · 25d ago BioNexus Gene Lab Corp. Calls for Malaysia–China Biotechnology Cooperation to Move Beyond Trade into Co-Development GlobeNewswire · 85d ago

PRIVATE STRATEGY · BY QUALIFICATION

The same data. A different seat.

The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.